Trial Profile
A Randomised, Double-Blind, Placebo Controlled, Multi-Center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients With Locally Advanced and/ or Metastatic Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 10 Apr 2023 Results assessing efficacy and safety of pazopanib monotherapy in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma published in the Journal of Clinical Oncology
- 06 Jul 2017 Results of retrospective analysis (n=343) assessing the prognostic significance of candidate cytokines and angiogenic factors for overall survival together with established clinical parameters and tumour burden, published in the British Journal of Cancer.
- 11 Oct 2016 Results of cost effectiveness of COMPARZ and VEG105192 trials presented at the 41st European Society for Medical Oncology Congress.